News | February 17, 2009

PET, PET/CT Studies Inched Up Just 4 Percent in 2008

February 17, 2009 - The total PET and PET/CT patient studies increased only 4 percent, from 1,457,400 to 1,520,800, compared to estimates for 2007 provided by respondents to a 2008 survey by IMV Medical Information Division, representing a slowdown in procedure growth.
Despite the 2008 figures represent a 35 percent increase over the same survey by IMV done in 2005, which estimated 1,129,900 patient studies were performed using PET or PET/CT, the recent slowdown may be caused by the Deficit Reduction Act (DRA) of 2005, indicated Lorna Young, senior director, Market Research at IMV.
“The estimated 1,520,800 clinical PET patient studies performed in 2008 represent a 35% increase over IMV’s 2005 estimate of 1,129,900 patient studies, for an average annual growth rate of 10.4 percent over the three-year period,” said Young. “With the advent of the Deficit Reduction Act (DRA) of 2005, related legislation against self-referral for standalone imaging centers, the increased scrutiny of third party insurers in their preauthorization processes and the reduction in the availability of capital, the market for PET purchases may continue to slow over the next few years.”
The report just released by IMV accounted for PET studies performed in 2,000 U.S. hospital and non-hospital sites, using fixed or mobile PET/CT or PET scanners.
Young added, “The PET market for fixed PET imaging units is still relatively early in its adoption cycle, as over half of the PET sites use a mobile service provider, while over 900 sites own one or more fixed PET or PET/CT scanners. A market forecast scenario presented in the report shows that over the next few years, 55 percent of the PET scanner demand will come from first buyers, who currently use mobile services, 30 percent will be replacement buyers and 15 percent will be additional buyers.”
The survey also noted that of the patient studies performed on PET or PET/CT scanners, 94 percent are for oncology applications, and 6 percent are for cardiology and neurology applications.

For more information: www.mvinfo.com

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init